GLI2
<div class="infobox infobox-gene">
<h3>GLI2 (GLI Family Zinc Finger 2)</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>GLI Family Zinc Finger 2</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>GLI2</td></tr> [@petrova2014]
<tr><td><strong>Chromosomal Location</strong></td><td>2q14.2</td></tr> [@gonzalezreyes2012]
<tr><td><strong>NCBI Gene ID</strong></td><td>[2736](https://www.ncbi.nlm.nih.gov/gene/2736)</td></tr> [@feijoo2011]
<tr><td><strong>OMIM</strong></td><td>[165230](https://omim.org/entry/165230)</td></tr> [@he2014]
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000074047](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000074047)</td></tr> [@corrales2006]
<tr><td><strong>UniProt (Protein)</strong></td><td>[P10070 (GLI2)](https://www.uniprot.org/uniprot/P10070)</td></tr> [@niewiadomski2014]
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Holoprosencephaly, Medulloblastoma, [Huntington's Disease](/diseases/huntingtons-disease)</td></tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
GLI2 (GLI Family Zinc Finger 2) encodes a 1586 amino acid zinc finger transcription factor that functions as the primary transcriptional activator of the [Hedgehog (Hh) signaling pathway](/mechanisms/hedgehog-pathway). GLI2 integrates signals from [Smoothened (SMO)](/genes/smo) and [Suppressor of Fused (SUFU)](/genes/sufu) to regulate target gene expression essential for neural development, adult neurogenesis, and neuronal survival. In contrast to [GLI1](/genes/gli1), which acts exclusively as a transcriptional activator, GLI2 possesses both activator and repressor domains, making it the primary effector that converts graded Hedgehog signals into differential transcriptional outputs. Dysregulation of GLI2 contributes to neurodegenerative disease, developmental brain malformations, and brain tumors.
Gene Structure and Expression
GLI2 spans approximately 264 kb on chromosome 2q14.2 and contains 13 exons encoding a 1586 amino acid protein. The gene produces multiple transcript variants through alternative splicing and alternative promoter usage, including a truncated N-terminal repressor form (GLI2ΔN) that lacks the activation domain. The promoter contains binding sites for SOX, POU, and Hedgehog-responsive elements that mediate autoregulatory feedback.
In the developing central nervous system, GLI2 is highly expressed in the ventral neural tube floor plate, where it is essential for specification of ventral cell fates including dopaminergic progenitors of the midbrain. In the adult brain, GLI2 expression persists in neurogenic niches — the subventricular zone (SVZ) and the hippocampal subgranular zone (SGZ) — and is maintained in [astrocytes](/cell-types/astrocytes), [cerebellar granule neurons](/cell-types/cerebellar-granule-cells), and [oligodendrocyte precursor cells](/cell-types/oligodendrocyte-precursor-cells). The [Allen Brain Atlas](https://human.brain-map.org/) shows broad expression across cortical regions with enrichment in the cerebellum, [hippocampus](/brain-regions/hippocampus), and thalamus.
Protein Function and Mechanism
GLI2 is a bifunctional zinc finger transcription factor containing five tandem C2H2 zinc finger domains that bind the consensus DNA sequence 5'-GACCACCCA-3' in target gene promoters. The protein is organized into distinct functional domains:
- N-terminal repressor domain (aa 1-272): Contains a Ski/Sno homology domain that recruits co-repressors including HDAC1 and mSin3A
- Zinc finger DNA-binding domain (aa 462-632): Five C2H2 zinc fingers that recognize the GLI consensus motif
- C-terminal activation domain (aa 1182-1586): Recruits CBP/p300 co-activators and mediates transcriptional activation
In the absence of Hedgehog ligand, [SUFU](/genes/sufu) binds GLI2 in the cytoplasm and promotes its partial proteolytic processing by the proteasome into a truncated N-terminal repressor form (GLI2R). This processing requires sequential phosphorylation by PKA, GSK3β, and CK1 kinases, which create a phosphodegron recognized by the β-TrCP/SCF E3 ubiquitin ligase complex. Upon Hedgehog pathway activation, [SMO](/genes/smo) triggers dissociation of the SUFU-GLI2 complex at the tip of the primary cilium, stabilizing full-length GLI2 activator (GLI2A) that translocates to the nucleus to drive target gene transcription.
Key transcriptional targets of GLI2 include [GLI1](/genes/gli1) (positive feedback amplifier), [PTCH1](/genes/ptch1) (negative feedback receptor), [PTCH2](/genes/ptch2), HHIP, MYCN, CCND1, FOXM1, and BCL2. GLI2 is the essential activator for floor plate induction, dopaminergic neuron specification, and cerebellar development.
Disease Associations
Alzheimer's Disease
GLI2 expression is reduced in the hippocampus and [entorhinal cortex](/brain-regions/entorhinal-cortex) of [Alzheimer's Disease (AD)](/diseases/alzheimers-disease) patients. Diminished Hedgehog-GLI2 signaling impairs adult hippocampal neurogenesis, contributing to cognitive decline. In [APP](/entities/app-protein)/PS1 transgenic mice, pharmacological activation of the Hedgehog pathway with SMO agonists restores GLI2 nuclear translocation, enhances neurogenesis in the SGZ, and improves spatial memory performance. GLI2 target genes including MYCN and CCND1 regulate neural progenitor proliferation, and their downregulation correlates with reduced dentate gyrus volume in AD.
Parkinson's Disease
GLI2 is critical for the specification and survival of midbrain [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the substantia nigra. During development, GLI2 cooperates with [FOXA2](/genes/foxa2) and [LMX1A](/genes/lmx1a) to establish the dopaminergic progenitor domain. In [Parkinson's Disease (PD)](/diseases/parkinsons-disease), reduced Hedgehog pathway activity and decreased GLI2 nuclear localization have been observed in surviving nigral [neurons](/entities/neurons). Conditional deletion of GLI2 in dopaminergic neurons accelerates their degeneration in MPTP-treated mice. GLI2-dependent expression of BDNF, GDNF, and anti-apoptotic factors provides autocrine neuroprotective signaling that is compromised in PD.
Huntington's Disease
In [Huntington's Disease (HD)](/diseases/huntingtons), mutant [huntingtin protein](/proteins/huntingtin) disrupts primary cilium structure and function, impairing cilium-dependent GLI2 processing and activation. R6/2 and zQ175 HD mouse models show reduced GLI2 activator levels and impaired Hedgehog target gene expression in striatal medium spiny neurons. Restoration of ciliary function or direct GLI2 activation partially rescues striatal neuron survival in these models.
Holoprosencephaly
Heterozygous loss-of-function mutations in GLI2 cause holoprosencephaly (HPE) type 9 (HPE9, OMIM 610829), a spectrum of forebrain midline developmental defects. GLI2-associated HPE ranges from severe alobar HPE with cyclopia to milder microforms with hypopituitarism. Over 40 pathogenic variants have been identified, predominantly truncating mutations in the zinc finger domain or activation domain. Penetrance is incomplete, suggesting modifier gene interactions with [SHH](/genes/shh), [SIX3](/genes/six3), and [ZIC2](/genes/zic2).
Common Variants
| Variant | Type | Clinical Significance |
|---------|------|----------------------|
| c.1681C>T (p.Arg561Ter) | Nonsense | Holoprosencephaly 9 (pathogenic) |
| c.680delG | Frameshift | Holoprosencephaly 9 (pathogenic) |
| c.2554C>T (p.Arg852Cys) | Missense | Pituitary anomalies (likely pathogenic) |
| rs11688767 | Intronic SNP | Associated with hippocampal volume in GWAS |
| c.4111G>A (p.Glu1371Lys) | Missense | VUS, activation domain |
Therapeutic Implications
GLI2 is a key pharmacological target at the convergence of Hedgehog signaling and neuroprotection:
- SMO agonists (SAG, purmorphamine): Indirect GLI2 activators that enhance neurogenesis; being explored for AD and PD neuroprotection
- GANT61: Direct GLI1/GLI2 DNA-binding inhibitor used in cancer research; helps define GLI2-dependent transcriptional programs in neurons
- Arsenic trioxide: Degrades GLI2 protein via direct binding; used to study loss-of-function phenotypes
- GLI2-targeted gene therapy: AAV-mediated GLI2 expression in dopaminergic neurons shows promise in preclinical PD models
- [HDAC](/entities/hdac-enzymes) inhibitors: Enhance GLI2 activator function by blocking co-repressor recruitment to the N-terminal domain
See Also
- [GLI1](/genes/gli1) — Hedgehog pathway transcriptional activator (positive feedback target of GLI2)
- [SMO](/genes/smo) — Smoothened receptor, upstream activator of GLI2
- [SUFU](/genes/sufu) — Suppressor of Fused, negative regulator that sequesters GLI2
- [PTCH1](/genes/ptch1) — Patched1 receptor, GLI2 transcriptional target and negative feedback component
- [SHH](/genes/shh) — Sonic Hedgehog ligand
- [LATS1](/genes/lats1) — Hippo pathway kinase with crosstalk to GLI2 via YAP/TAZ
External Links
- [NCBI Gene: GLI2](https://www.ncbi.nlm.nih.gov/gene/2736)
- [UniProt: P10070](https://www.uniprot.org/uniprot/P10070)
- [OMIM: 165230](https://omim.org/entry/165230)
- [GeneCards: GLI2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GLI2)
- [Allen Brain Atlas: GLI2](https://human.brain-map.org/)
- [GTEx Portal: GLI2](https://gtexportal.org/home/gene/GLI2)
References
[Bai CB et al., All mouse ventral spinal cord patterning by Hedgehog is Gli dependent and involves an activator function of Gli3 (2004) (2004)](https://doi.org/10.1016/j.devcel.2004.02.001)
[Matise MP et al., Gli2 is required for induction of floor plate and adjacent cells, but not most ventral neurons in the mouse central nervous system (1998) (1998)](https://doi.org/10.1242/dev.125.15.2759)
[Pan Y et al., Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation (2006) (2006)](https://doi.org/10.1128/MCB.26.9.3365-3377.2006)
[Roessler E et al., Mutations in the human Sonic Hedgehog gene cause holoprosencephaly (1996) (1996)](https://doi.org/10.1038/ng0996-70)
[Unknown, Petrova R & Bhatt R, Hedgehog-Gli pathway in brain development and disease (2014) (2014)](https://doi.org/10.1016/j.neulet.2014.04.033)
[Gonzalez-Reyes LE et al., Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit (2012) (2012)](https://doi.org/10.1016/j.neuron.2012.09.009)
[Feijoo CG et al., Sonic hedgehog mediates the proliferative and anti-apoptotic effects of lithium in neural progenitors (2011) (2011)](https://doi.org/10.1002/jcp.22424)
[He W et al., GDC-0449 inhibits Hedgehog signaling and induces apoptosis in medulloblastoma cells (2014) (2014)](https://doi.org/10.1016/j.canlet.2014.09.025)
[Corrales JD et al., The level of sonic hedgehog signaling regulates the complexity of cerebellar foliation (2006) (2006)](https://doi.org/10.1242/dev.02351)
[Niewiadomski P et al., Gli protein activity is controlled by multisite phosphorylation in vertebrate Hedgehog signaling (2014) (2014)](https://doi.org/10.1016/j.celrep.2013.12.003)Pathway Diagram
The following diagram shows the key molecular relationships involving GLI2 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)